This partiality in overlap, while possibly indicating a core of antiviral genes with the potential of blocking infection of viruses such as EHDV-TAU (e.g., IFIT1-3, APOL2, IFIH1), likely contributes to the differences in their antiviral programs (e.g., their differential potency in restricting hMPV-GFP). The gene discussed is APOL2; the disease is infection.